An APOC1+ inflammatory CAF-like state drives a senescent, treatment-resistant niche in rheumatoid arthritis
Risa YoshiharaiD, Sotaro NakajimaiD, Reo Yamazato, Tomoya Yoshida, Ikuo TakazawaiD, Yasunori OmataiD, Teh-Wei WangiD, Kazuyoshi IshigakiiD, Takahiro ItamiyaiD, Mineto OtaiD, Yoichi YasunagaiD, Yuichiro FujiedaiD, Takumi MatsumotoiD, Hirofumi ShodaiD, Kazuhiko YamamotoiD, Naoto TamuraiD, Toshihide MimuraiD, Koichiro OhmuraiD, Akio MorinobuiD, Tatsuya AtsumiiD, Yoshiya TanakaiD, Tsutomu TakeuchiiD, Yutaka Suzuki, Makoto NakanishiiD, Tomohisa OkamuraiD, , Keishi FujioiD
Abstract
ObjectivesRheumatoid arthritis (RA) synovitis frequently persists despite cytokine-targeted therapies, suggesting the existence of pathogenic stromal programs that sustain chronic inflammation independently of canonical immune pathways. Although synovial fibroblasts (SF) are increasingly implicated in treatment resistance, the pathogenic fibroblast states driving refractory disease and their therapeutic vulnerabilities remain poorly defined. MethodsWe integrated multimodal single-cell and spatial profiling of synovial tissue from 54 patients with RA with prospective treatment-response data and functional studies in human fibroblasts and experimental arthritis models. ResultsWe identified a C-X-C motif chemokine 12 (CXCL12)hi Apolipoprotein C1 (APOC1)+ fibroblast population selectively enriched in treatment-refractory synovitis. Spatial analyses demonstrated that these fibroblasts establish CXCL12-dependent plasmablast niches within inflamed synovium, resembling inflammatory cancer-associated fibroblasts (iCAF) that orchestrate immune cell recruitment in the tumor microenvironment. CXCL12hi APOC1+ fibroblasts exhibited a senescence-associated iCAF-like transcriptional program characterized by STAT3-C/EBP activation and APOC1 expression and were associated with poor response to TNF and IL-6 pathway inhibition. Mechanistically, APOC1 knockdown in RA-SF attenuated invasive mesenchymal behavior and disrupted senescence-associated inflammatory programs, identifying APOC1 as a central regulator of pathogenic fibroblast reprogramming. Importantly, genetic or pharmacological elimination of senescent cells ameliorated experimental arthritis and enhanced the efficacy of TNF blockade. ConclusionsThese findings implicate iCAF-like fibroblasts with senescent properties as a mechanistic driver of refractory RA synovitis and highlight stromal senescence programs as preclinically actionable therapeutic targets beyond cytokine inhibition.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Synovial fibroblast niche shapes the efficacy - safety dynamics of JAK inhibition in rheumatoid arthritis
Ana Županič, Sam G. Edalat, … Mojca Frank‐Bertoncelj·bioRxiv·Mar 25, 2026
- CAR-macrophage immunotherapy targeting fibroblast-like synoviocytes ameliorates inflammatory and degenerative arthritis
Yangli Xu, Zhuqian Wang, … Chao Liang·bioRxiv·Oct 28, 2026
- Fibroblasts sense spatial proximity via an EGFR CREB5 axis to restore quiescent synovial lining in remission rheumatoid arthritis
Sonia Presti, Ksenia S. Anufrieva, … Kevin S. Wei·bioRxiv·Dec 12, 2025
- Reprogramming of lipid secretome in senescent synovial fibroblasts ameliorate osteoarthritis development
- Heterogeneity of Inflammation-associated Synovial Fibroblasts in Rheumatoid Arthritis and Its Drivers
M. H. Smith, V. R. Gao, … A. Y. Rudensky·bioRxiv·Feb 28, 2022
- Spatial patterning of fibroblast TGFβ signaling underlies treatment resistance in rheumatoid arthritis
Kartik Bhamidipati, Alexa B. R. McIntyre, … Kevin Wei·Nature ImmunologyPeer-reviewed·Jan 15, 2026